

Important information regarding forward-looking statements: This presentation contains forward-looking statements within the meaning of federal and state securities laws that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" and include, but are not limited to, statements of management's expectations regarding the company's performance, sales force and customer base, growth, initiatives, performance and benefits of the company's manufacturing partners and controlled environment agriculture initiative, strategy and new product introductions; projections regarding revenue, margins, expenses, earnings per share, foreign currency fluctuations, tax rates, uses of cash and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "outlook," "project," "anticipate," "estimate," "intend," "plan," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words.


The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

- adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
- risk that direct selling laws and regulations in any of our markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to our business model or negatively impacts our revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse actions or events;
- any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
- risk of foreign currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
- uncertainties regarding the future performance of the company's manufacturing partners and controlled environment agriculture initiative;
- risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
- regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit the company's ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;
- unpredictable economic conditions and events globally;
- uncertainties related to interpretation of, and forthcoming regulations under, the recently enacted U.S. tax reform legislation; the company's future tax-planning initiatives; any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and
- continued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided and the company assumes no duty to update the forward-looking statements contained in this presentation to reflect any change except as required by law.











2018 Successes & Challenges

SUCCESSES

- Customers +16%
- Sales leaders +16% from Q1
- Revenue +18%
- Growth in nearly every reporting segment
- Successful debt refinance
- Acquisitions increase growth potential

CHALLENGES

- Strengthening of US dollar
- Shift in technology strategy
- China trade uncertainty
- U.S. tax reform
- Argentina currency devaluation

2018 Accountability Report

2018 GUIDANCE

(Feb. 2018)

2018 ACTUAL

Annual Revenue

\$2.44 B - \$2.49 B

7-9% growth, with a +2-3% fx impact \$2.68 B

+18% growth 0.5% fx impact

Operating Margin

12.0% - 12.4%

11.9%*

EPS


\$3.45 - \$3.65

\$3.52*

^{*} Non-GAAP, see reconciliation.







600 MILLION

Meals donated to malnourished children around the world since 2002.



22 LIBRARIES

Completed since 2008. As a result, 6,700 children now have access to tools that will enable them to learn and achieve their educational goals.



THE Heart

OF WHO

WEARE

18,500


Life-saving heart surgeries in Greater China and Southeast Asia



30,870

children screened for visual impairments in Colombia, Argentina and the United States.











Business Essential

Capital & Finance

Sustainability

Technology











TO IMPROVE LIVES WITH REWARDING BUSINESS OPPORTUNITIES, INNOVATIVE PRODUCTS, AND AN ENRICHING, UPLIFTING CULTURE.




OUR VISION

TO BECOME THE WORLD'S LEADING

BUSINESS OPPORTUNITY

PLATFORM









CUSTOMER FIRST

CLOUD FIRST

SECURITY FIRST



Engaging Platforms







to build a socially-enabled business to attract more customers

CLOUD

agile | scalable | resilient

Partnering with leading technology providers to deliver a world-class customer experience.



Amazon Web Services and the "Powered by AWS" logo are trademarks of Amazon.com, Inc. or its affiliates in the United States and/or other countries. Aliyun and its logo are trademarks of Alibaba or its affiliates in the United States and/or other countries.

Cloud Benefits













DRIVE DEVICE PLATFORM

BUILD FOUNDATIONAL BRANDS

OPTIMIZE PORTFOLIO



Enabling Products

Ceauty & wellness







Beauty Line Expansion

agelOC LumiSpa













Beauty Line Expansion

ageLOC Galvanic & Facial Spa

















Controlled Environment Agriculture (CEA) + Nu Skin Science

- Pure, safe and effective ingredients (6S quality guarantee)
- High density nutrients
- Traceable from seed to solution
- Sustainably sourced

THE SOLUTION

Our best can get even better.

Through Controlled Environment Agriculture, Nu Skin infuses the best of **nature**, the latest in **science**, and the most advanced **technology** into pure, safe and sustainable products that deliver real results.

FUTURE PRODUCTS



OPTIMIZE VELOCITY

CUSTOMER LOYALTY

ENHANCE ROADMAP




Empowering Programs



- Flexible lifestyle
- Earning potential
- Community & purpose

CUSTOMER DEMAND









VELOCITY SHARE BUILD LEAD

+26% customer acquisition

...which led to a 16% increase in active customers Number of People Being Paid



pre-VELOCITY

post-VELOCITY

44% increase in payees since VELOCITY introduced*

*VELOCITY not yet rolled out in EMEA. Also excludes Mainland China, which operates under a different business model.



AND ELJONO KEY INTIATIVES

2019

- **PLATFORMS:** Migrate to the Cloud
- **PRODUCTS:** Expand beauty device platform; introduce CEA
- **PROGRAMS:** Complete rollout of

FUTURE

- **PLATFORMS:** Expand social tools
- **PRODUCTS:** Infuse CEA into portfoilio
- PROGRAMS: Optimize VELOCITY




REVENUE GROWTH
CUSTOMER GROWTH
SALES LEADER GROWTH




Global Growth
Profile

GLOBAL GROWTH

(in billions USD)







2018: 21% LC revenue growth

Beauty device expansion (LumiSpa, ageLOC Me, Galvanic)

Regulatory environment update

2019 projected LC growth of 7 to 10%





2018: 20% LC revenue growth

Strong growth in Latin America and Pacific

Argentina highly inflationary

2019 projected LC growth of 6 to 8%



2018: 1% LC revenue growth

Effective use of local social platforms

Effective product localization (180°, Korea 20)

2019 projected LC growth of 0 to 2%








Social sharing expansion – TR90, Scion

Focus on demographic expansion

2019 projected LC growth of 8 to 10%






2018: (2%) LC revenue growth


Shifting demographics through social sharing

Improving trends in challenging environment

2019 projected LC growth of (1) to 1%








2018: 11% LC revenue growth

Effective use of social promotions

Strong LumiSpa introduction

2019 projected LC growth of 0 to 2%















Manufacturing Platform Benefits

- Innovation & speed
- Gross margin benefit to core business
- High growth opportunity
- U.S. profit





CASEPAK







60,000,000+

units per year production capacity



195,000

sq ft. state-of-the-art facility



300+ employees

production lines



Turnkey OTC, Personal Care & Medical Device Mfg.

CURRENT SUPPLIER

WASATCH





16,000 units per batch

118,000 units per batch (7X)

Older blending system

State-of-the-art blending technology

Assurance of Supply

Quality

15 week lead time

12 week lead time

Service

Air freight required

Air freight eliminated



Cost

Scale-up in 6 months

Scale-up in 3 months



Innovation







years from founding to profitability

100,000

sq ft. state-of-the-art facility





75+ employees

production lines



vegan gelcap technology





ELEVATE

Open global supply



of Supply

50% reduction in lead time



Service

20% savings




Cost

Scale in 3 months



Innovation









23

years in business



Custom Packaging & Fulfillment



160+

current customers





CASEPAK

Flexibility of suppliers to increase capability



Assurance of Supply

Domestic inventory stocking option



Service

Improved pricing



Cost

Innovative short and long term solutions



Innovation







Steve Lindsley
President, Groviv











PATENTED TECHNOLOGY, WORLD CLASS SCIENCE

GroPod™ GROWING




GroCenter INNOVATING



GroLab ANALYZING

Self-Learning OPTIMIZING









Important information regarding forward-looking statements: This presentation contains forward-looking statements within the meaning of federal and state securities laws that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" and include, but are not limited to, statements of management's expectations regarding the company's performance, sales force and customer base, growth, initiatives, performance and benefits of the company's manufacturing partners and controlled environment agriculture initiative, strategy and new product introductions; projections regarding revenue, margins, expenses, earnings per share, foreign currency fluctuations, tax rates, uses of cash and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "outlook," "project," "anticipate," "estimate," "intend," "plan," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

- adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
- risk that direct selling laws and regulations in any of our markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to our business model or negatively impacts our revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse actions or events;
- any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
- risk of foreign currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
- uncertainties regarding the future performance of the company's manufacturing partners and controlled environment agriculture initiative;
- risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
- regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit the company's ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;
- unpredictable economic conditions and events globally;
- uncertainties related to interpretation of, and forthcoming regulations under, the recently enacted U.S. tax reform legislation; the company's future tax-planning initiatives; any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and
- continued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided and the company assumes no duty to update the forward-looking statements contained in this presentation to reflect any change except as required by law.



2019 Guidance

* Non-GAAP, see reconciliation.

Annual Revenue

\$2.76 B - \$2.82 B

5 to 7% constant currency growth* (2 to 3%) foreign currency impact

Operating Margin

12.3% - 12.8%

EPS

\$3.80 - \$4.05


33% to 36% tax rate


2019 Projected Revenue Growth


Consolidated Local Currency Growth: 5 to 7%			
Mainland China	7 to 10%		
Americas/PAC	6 to 8%		
South Korea	0 to 2%		
Southeast Asia	8 to 10%		
Japan	-1 to 1%		
Hong Kong/Taiwan	0 to 2%		
EMEA	1 to 3%		
Manufacturing	8 to 10%		
Global FX Impact: (2 to 3%)			
Consolidated GAAP Growth: 3 to 5%			











Other Income Expense – 2019 Projected

Interest Income	\$5 M
Interest Expense	(\$22 M)
FX Gains / (Losses) & Other	(\$0 - \$5 M)
Total Income / (Expense)	(\$17 - \$22 M)



2019 Consolidated Breakout

	Consolidated	Nu Skin	Manufacturing	Grow Platform
Rev	2.76 - 2.82 B	4 - 7% Growth	8 – 10% Growth	
GM	76 - 77%	78 - 79%	26 – 28%	
SE	39 - 40%	41 - 42%		
G&A	24.2 - 24.6%	23.9 - 24.5%	15.0 – 17.0%	
Ol	12.3 - 12.8%	12.8–13.2%	12.0 – 13.5%	(\$8 – \$10 M) Expense*
Tax	33 - 36%			
EPS	3.80 - 4.05			



Invest to grow the business

Protect a strong balance sheet

for Cash Use

Priorities

Pay a healthy dividend

Repurchase stock/Pay down debt





2019 Cash Flow Modeling

	2018	2019 Projections
D&A	\$83 M	\$70 M - \$80 M
Capital expense	\$70 M	\$80 M - \$100 M
Debt reduction	\$31 M*	\$40 M - \$50 M
Dividend payments	\$81 M	\$83 M

^{*}Net of refinancing



NU SKIN ENTERPRISES, INC. Reconciliation of Earnings Per Share Excluding Impact of Restructuring and Tai Reform to GAAP Earnings Per Share

(in thousands, except per share amounts)

Years Ended

NU SKIN ENTERPRISES, INC. Reconciliation of Operating Margin Excluding Impact of Restructuring to GAAP Operating Margin

(in thousands, except per share amounts)

	December 31,						
	2018		,	2017			Year Ended
Net income	\$ 121,88	7	\$ 12	29,437		<u>u</u>	2018
Impact of restructuring and impairment: Restructuring and impairment	70,68	6		_	Operating income	\$	240,860
Inventory write-off Income tax impact	7,24 (1,08			_	Impact of restructuring and impairment: Restructuring and impairment		70,686
Impact of tax reform on provision for income taxes Adjusted net income	\$ 198,72	<u></u>		47,729 77,166	Inventory write-off Adjusted operating income	<u>s</u>	7,240 318,786
Diluted earnings per share	\$ 2.1		\$	2.36	Operating margin		9.0%
Diluted earning per share, excluding restructuring and tax reform impact	\$ 3.5	2	\$	3.23	Operating margin, excluding restructuring impact		11.9%
Weighted-average common shares outstanding (000s):	56,47	6		54,852	Revenue	\$	2,679,008

Constant-currency revenue growth is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's revenue